BLTE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 115262 min ago

@ $47.00

Wydano: 13 vas. 2024 @ 16:30

Zwrot: -12.17%

Poprzedni sygnał: vas. 9 - 16:43

Poprzedni sygnał: Sprzedaż

Zwrot: 0.90 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:13):

Stats
Dzisiejszy wolumen	5 840.00
Średni wolumen	40 391.00
Kapitalizacja rynkowa	1.23B
EPS	$0 ( 2024-03-12 )
Następna data zysków	( $-0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.69
ATR14	$0.294 (0.71%)

Belite Bio, Inc Korelacja

10 Najbardziej pozytywne korelacje
VLCN	0.958
HIBB	0.957
IART	0.953
EMKR	0.935
VBFC	0.935
IEP	0.934
IVAC	0.929
MLAB	0.926
GOGL	0.924
CATB	0.924

10 Najbardziej negatywne korelacje
SMCI	-0.957
OPRA	-0.953
VIRI	-0.951
HGBL	-0.949
NVDA	-0.949
TZPS	-0.944
RXST	-0.943
AIB	-0.942
FRBN	-0.941
MLAI	-0.938

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Belite Bio, Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-399 000 (0.00 %)
EPS:	$-1.190

FY	2023
Przychody:	$0
Zysk brutto:	$-399 000 (0.00 %)
EPS:	$-1.190

FY	2022
Przychody:	$0
Zysk brutto:	$-198 000 (0.00 %)
EPS:	$-0.620

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.401

Financial Reports:

No articles found.

Belite Bio, Inc

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Aktualne aktualizacje dla Belite Bio, Inc [BLTE]

Upcoming Earnings Alert